세계의 분자진단 시장 : 산업 분석 - 규모, 점유율, 성장, 동향, 예측(2024-2031년)

Molecular Diagnostics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024 - 2031

US $ 4,995 ￦ 6,977,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,190,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,866,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 세계의 분자진단 시장에 대한 종합적인 보고서를 발표했습니다. 이 보고서는 시장 성장 촉진요인, 동향, 기회 및 과제 등 주요 시장 역학을 상세하게 분석하고 시장 구조에 대한 자세한 인사이트를 제공합니다.

주요 인사이트

• 분자진단 시장 규모(2024년) : 232억 달러
• 예측 시장 규모(2031년) : 356억 달러
• 세계 시장 성장률(CAGR 2024-2031년) : 6.2%

분자진단 시장-조사 범위 :

분자진단은 유전체이나 프로테옴 중의 생물학적 마커를 해석하여 질환의 진단이나 모니터링을 실시합니다. 이 시장에는 중합효소 연쇄반응(PCR), 차세대 시퀀싱(NGS), in situ 하이브리드화 등의 기술이 포함됩니다. 분자진단은 유전성 질환, 감염증, 특정 암의 진단에 필수적이며, 환자 고유의 질환 프로파일에 대한 인사이트를 제공함으로써 맞춤형 의료에서 중요한 역할을 하고 있습니다.

시장 성장 촉진요인 :

세계의 분자진단 시장은 유전성 질환과 감염증의 유병률 증가, 맞춤형 의료에 대한 수요 증가 등 몇 가지 중요한 요인에 의해 견인되고 있습니다. 고처리량 시퀀싱 및 첨단 바이오인포매틱스 툴 개발과 같은 분자진단 기술의 진보는 진단 정확도와 효율성을 향상시키고 있습니다. 건강 관리 지출 증가와 예방 의료에 대한 관심 증가는 시장의 성장에 더욱 기여합니다. 또한 신흥 시장에서의 분자진단의 확대와 종양학에서의 분자검사의 채용확대가 시장확대의 새로운 기회를 창출하고 있습니다.

시장 성장 억제요인 :

유망한 성장 전망에도 불구하고 분자진단 시장은 고비용과 복잡한 규제 요건과 관련된 문제에 직면하고 있습니다. 고급 진단 장비 및 검사 가격이 높기 때문에 자원이 부족한 환경과 신흥 국가에서의 액세스가 제한될 수 있습니다. 또한, 분자진단 검사의 승인과 상환을 위한 엄격한 규제 과정은 시장 진입을 방해하고 기술 혁신을 지연시킬 수 있습니다. 연구개발에 대한 지속적인 투자의 필요성과 규제기준 준수의 필요성은 시장 성장의 큰 장벽이 됩니다.

시장 기회 :

분자진단 시장은 기술 진보, 인구 동향, 건강 관리 요구의 진화로 큰 비즈니스 기회를 제공합니다. 휴대형 진단 기기의 개발이나 진단에 있어서의 인공지능(AI)의 통합이라고 하는 분자진단 기술의 혁신은 시장 성장의 새로운 길을 열고 있습니다. 암, 감염증, 유전성 질환 등 다양한 치료 영역에서 분자진단의 응용이 진행되고 있는 것이 시장 범위를 확대하고 있습니다. 전략적 파트너십, 연구개발 투자, 비용 효율적인 진단 솔루션의 소개는 새로운 비즈니스 기회를 활용하고 시장에서 리더십을 유지하는 데 필수적입니다.

이 보고서에서 다루는 주요 질문

• 세계 분자진단 시장의 성장을 가속하는 주요 요인은 무엇인가?
• 다양한 건강 관리 환경에서 어떤 진단 기술 및 용도가 분자진단 약물의 채택을 촉진하고 있는가?
• 기술의 진보는 분자진단 시장 경쟁 구도를 어떻게 바꾸고 있는가?
• 분자진단 시장에 기여하는 주요 기업은 어디인가? 시장 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계의 분자진단 시장에서 새로운 동향 및 전망은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장의 범위 및 정의
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
  • 주요 동향
• 분자진단 시장 : 밸류체인
  • 제조업체 일람
  • 리셀러 일람
  • 수익성 분석
• 거시경제 요인
  • 세계의 분야별 전망
  • 세계의 GDP 성장 전망
  • 세계의 상위 시장 개요
• 예측 요인-관련성 및 영향
• COVID-19의 영향 평가
• 기술의 진보
• 질병 역학
• Porter's Five Forces 분석
• 규제 시나리오
• 제품 채용 분석
• 상위 시장 분석

제3장 가격 동향 분석(2024-2031년)

• 주요 하이라이트
• 제품 가격에 영향을 미치는 주요 요인
• 제품 유형별 가격
• 지역별 가격 및 제품 취향

제4장 세계의 분자진단 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

• 주요 하이라이트
  • 제품 유형별 시장 규모(단위) 예측
  • 시장 규모 및 전년대비 성장률
  • 절대적인 $ 기회
• 시장 규모의 분석 및 예측
  • 과거 시장 규모 분석(2019-2023년)
  • 현재 시장 규모 예측(2024-2031년)
• 세계의 분자진단 시장 전망 : 제품 유형별
  • 서문 : 주요 조사 결과
  • 시장 규모와 수량(단위)의 과거 분석 : 제품 유형별(2019-2023년)
  • 현재 시장 규모 및 수량(유닛) 예측 : 제품 유형별(2024-2031년)
    • 기기
      • 중합효소 연쇄반응(PCR) 시스템
      • 하이브리드화(in-situ 하이브리드화와 물고기) 시스템
      • DNA 시퀀싱과 차세대 시퀀싱 플랫폼
      • 마이크로어레이
    • 시약
      • 항체
      • DNA 템플릿
      • DNA 폴리머라제
      • 올리고뉴클레오티드 프라이머
      • 데옥시리보뉴클레오티드 트리포스페이트(dNTP)
      • 버퍼
    • 분석 키트
    • 소모품
• 시장의 매력 분석 : 제품 유형별
• 세계의 분자진단 시장 전망 : 질환 영역별
  • 서문 : 주요 조사 결과
  • 시장 규모의 역사적 분석 : 질환 영역별(2019-2023년)
  • 현재 시장 규모 예측 : 질환 영역별(2024-2031년)
    • 감염증
    • 당뇨병
    • 심장병학
    • 종양학
    • 신장학
    • 자가면역질환
    • 피부과
    • 상처 케어
    • 기타
• 시장의 매력 분석 : 질환 영역별
• 세계 분자진단 시장 전망 : 최종 사용자별
  • 서문 : 주요 조사 결과
  • 시장 규모의 과거 분석 : 최종 사용자별(2019-2023년)
  • 현재 시장 규모 예측 : 최종 사용자별(2024-2031년)
    • 병원 및 클리닉
    • 진단 실험실
    • 학술연구기관
    • 바이오의약품기업
• 시장의 매력 분석 : 최종 사용자별

제5장 세계의 분자진단 시장 전망 : 지역별

• 주요 하이라이트
• 시장 규모의 과거 분석 : 지역별(2019-2023년)
• 현재 시장 규모 예측 : 지역별(2024-2031년)
  • 북미
  • 유럽
  • 동아시아
  • 남아시아와 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역별

제6장 북미의 분자진단 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제7장 유럽의 분자진단 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제8장 동아시아의 분자진단 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제9장 남아시아 및 오세아니아의 분자진단 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제10장 라틴아메리카의 분자진단 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제11장 중동 및 아프리카의 분자진단 시장 전망 : 과거(2019-2023년) 및 예측(2024-2031년)

제12장 경쟁 구도

• 시장 점유율 분석(2024년)
• 시장 구조
  • 시장별 경쟁 강도 매핑
  • 경쟁 대시보드
• 기업 프로파일(상세-개요, 재무, 전략 및 최근 동향)
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Hoffmann la roche
  • Qiagen NV
  • Illumina, Inc.
  • DiaSorin SpA
  • Hologic Inc.
  • Siemens Healthineers AG
  • Seegene, Inc.
  • Grifols, SA
  • bioMerieux
  • QuidelOrtho Corporation
  • RapidBio
  • Abbott Laboratories
  • Danaher Corporation

제13장 부록

• 조사 방법
• 조사의 전제
• 두자어 및 약어

AJY

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global molecular diagnostics market. This report provides an in-depth analysis of key market dynamics, including drivers, trends, opportunities, and challenges, and offers detailed insights into the market structure.

Key Insights:

• Molecular Diagnostics Market Size (2024E): USD 23.2 Bn
• Projected Market Value (2031F): USD 35.6 Bn
• Global Market Growth Rate (CAGR 2024 to 2031):6.2%

Molecular Diagnostics Market - Report Scope:

Molecular diagnostics involve the analysis of biological markers in the genome and proteome to diagnose and monitor diseases. This market includes technologies like polymerase chain reaction (PCR), next-generation sequencing (NGS), and in situ hybridization. Molecular diagnostics are essential for diagnosing genetic disorders, infectious diseases, and certain cancers, and play a crucial role in personalized medicine by providing insights into patient-specific disease profiles.

Market Growth Drivers:

The global molecular diagnostics market is driven by several key factors, including the increasing prevalence of genetic disorders and infectious diseases, and the growing demand for personalized medicine. Advancements in molecular diagnostic technologies, such as the development of high-throughput sequencing and advanced bioinformatics tools, are enhancing diagnostic accuracy and efficiency. The rise in healthcare expenditures and the increasing focus on preventive healthcare further contribute to market growth. Additionally, the expansion of molecular diagnostics in emerging markets and the growing adoption of molecular tests in oncology are creating new opportunities for market expansion.

Market Restraints:

Despite promising growth prospects, the molecular diagnostics market faces challenges related to high costs and complex regulatory requirements. The high price of advanced diagnostic equipment and tests can limit access in low-resource settings and emerging economies. Additionally, the stringent regulatory processes for approval and reimbursement of molecular diagnostic tests can impede market entry and slow down innovation. The need for continuous investment in R&D and the necessity to comply with regulatory standards pose significant barriers to market growth.

Market Opportunities:

The molecular diagnostics market presents significant opportunities driven by technological advancements, demographic trends, and evolving healthcare needs. Innovations in molecular diagnostic technologies, such as the development of portable diagnostic devices and the integration of artificial intelligence (AI) in diagnostics, are opening new avenues for market growth. The increasing application of molecular diagnostics in various therapeutic areas, including oncology, infectious diseases, and genetic disorders, is expanding the market scope. Strategic partnerships, investments in R&D, and the introduction of cost-effective diagnostic solutions are essential for capitalizing on emerging opportunities and sustaining market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the molecular diagnostics market globally?
• Which diagnostic technologies and applications are driving the adoption of molecular diagnostics in different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the molecular diagnostics market?
• Who are the key players contributing to the molecular diagnostics market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global molecular diagnostics market?

Competitive Intelligence and Business Strategy:

Leading players in the global molecular diagnostics market, including Roche Diagnostics, Abbott Laboratories, and Thermo Fisher Scientific, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced diagnostic technologies, including next-generation sequencing and real-time PCR systems, catering to diverse diagnostic needs and clinical applications. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practices, and patient education fosters market growth and enhances diagnostic accuracy and outcomes.

Key Companies Profiled:

• Becton, Dickinson and Company
• Bio-Rad Laboratories In
• Merck KgaA
• Thermo Fisher Scientific Inc
• Agilent Technologies, Inc.
• F. Hoffman - La Roche Ltd.
• Illumina, Inc.
• Qiagen N.V.
• Hologic Inc.
• Siemens Healthineers AG
• Seegene, Inc.
• DiaSorin S.p.A
• Grifols, S.A.
• bioMerieux
• QuidelOrtho Corporation
• RapidBio

Molecular Diagnostics Market Research Segmentation

By Product Type:

• Instruments
• Reagent
• Assay Kits
• Consumables

By Disease Area:

• Infectious Disease
• Diabetes
• Cardiology
• Oncology
• Nephrology
• Autoimmune Disease
• Dermatology
• Wound Care
• Others

By End-use:

• Hospitals & Clinics
• Diagnostics Laboratories
• Academic and Research Institutes
• Biopharmaceutical Companies

By Region:

• North America
• Europe
• East Asia
• South Asia & Oceania
• Latin America
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Molecular Diagnostics Market Snapshot, 2024 - 2031
• 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Molecular Diagnostics Market: Value Chain
  • 2.3.1. List of Manufacturers
  • 2.3.2. List of Distributors
  • 2.3.3. Profitability Analysis
• 2.4. Macro-Economic Factors
  • 2.4.1. Global Sectorial Outlook
  • 2.4.2. Global GDP Growth Outlook
  • 2.4.3. Global Parent Market Overview
• 2.5. Forecast Factors - Relevance and Impact
• 2.6. Covid-19 Impact Assessment
• 2.7. Technology Advancement
• 2.8. Disease Epidemiology
• 2.9. Porter Five Force's Analysis
• 2.10. Regulatory Scenario
• 2.11. Product Adoption Analysis
• 2.12. Parent Market Analysis

3. Price Trend Analysis, 2024 - 2031

• 3.1. Key Highlights
• 3.2. Key Factors Impacting Product Prices
• 3.3. Prices by Product Type
• 3.4. Regional Prices and Product Preferences

4. Global Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 4.1. Key Highlights
  • 4.1.1. Market Volume (Units) Projections, by Product Type
  • 4.1.2. Market Size and Y-o-Y Growth
  • 4.1.3. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn ) Analysis and Forecast
  • 4.2.1. Historical Market Size Analysis, 2019-2023
  • 4.2.2. Current Market Size Forecast, 2024 - 2031
• 4.3. Global Molecular Diagnostics Market Outlook: Product Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis by Product Type, 2019-2023
  • 4.3.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
    • 4.3.3.1. Instruments
      • 4.3.3.1.1. Polymerase Chain Reaction (PCR) Systems
      • 4.3.3.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
      • 4.3.3.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
      • 4.3.3.1.4. Microarrays
    • 4.3.3.2. Reagent
      • 4.3.3.2.1. Antibodies
      • 4.3.3.2.2. DNA Template
      • 4.3.3.2.3. DNA Polymerase
      • 4.3.3.2.4. Oligonucleotide Primers
      • 4.3.3.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
      • 4.3.3.2.6. Buffer
    • 4.3.3.3. Assay Kits
    • 4.3.3.4. Consumables
• 4.4. Market Attractiveness Analysis: Product Type
• 4.5. Global Molecular Diagnostics Market Outlook: Disease Area
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Bn ) Analysis By Disease Area, 2019-2023
  • 4.5.3. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
    • 4.5.3.1. Infectious Disease
    • 4.5.3.2. Diabetes
    • 4.5.3.3. Cardiology
    • 4.5.3.4. Oncology
    • 4.5.3.5. Nephrology
    • 4.5.3.6. Autoimmune Disease
    • 4.5.3.7. Dermatology
    • 4.5.3.8. Wound Care
    • 4.5.3.9. Others
• 4.6. Market Attractiveness Analysis: Disease Area
• 4.7. Global Molecular Diagnostics Market Outlook: End User
  • 4.7.1. Introduction / Key Findings
  • 4.7.2. Historical Market Size (US$ Bn ) Analysis by End User, 2019-2023
  • 4.7.3. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
    • 4.7.3.1. Hospitals & Clinics
    • 4.7.3.2. Diagnostics Laboratories
    • 4.7.3.3. Academic and Research Institutes
    • 4.7.3.4. Biopharmaceutical Companies
• 4.8. Market Attractiveness Analysis: End User

5. Global Molecular Diagnostics Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Bn ) Analysis by Region, 2019-2023
• 5.3. Current Market Size (US$ Bn ) Forecast by Region, 2024 - 2031
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 6.2.1. by Country
  • 6.2.2. by Product Type
  • 6.2.3. By Disease Area
  • 6.2.4. by End User
• 6.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 6.4.1. Instruments
    • 6.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 6.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 6.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 6.4.1.4. Microarrays
  • 6.4.2. Reagent
    • 6.4.2.1. Antibodies
    • 6.4.2.2. DNA Template
    • 6.4.2.3. DNA Polymerase
    • 6.4.2.4. Oligonucleotide Primers
    • 6.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 6.4.2.6. Buffer
  • 6.4.3. Assay Kits
  • 6.4.4. Consumables
• 6.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 6.5.1. Infectious Disease
  • 6.5.2. Diabetes
  • 6.5.3. Cardiology
  • 6.5.4. Oncology
  • 6.5.5. Nephrology
  • 6.5.6. Autoimmune Disease
  • 6.5.7. Dermatology
  • 6.5.8. Wound Care
  • 6.5.9. Others
• 6.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 6.6.1. Hospitals & Clinics
  • 6.6.2. Diagnostics Laboratories
  • 6.6.3. Academic and Research Institutes
  • 6.6.4. Biopharmaceutical Companies
• 6.7. Market Attractiveness Analysis

7. Europe Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 7.2.1. by Country
  • 7.2.2. by Product Type
  • 7.2.3. By Disease Area
  • 7.2.4. by End User
• 7.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkiye
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 7.4.1. Instruments
    • 7.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 7.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 7.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 7.4.1.4. Microarrays
  • 7.4.2. Reagent
    • 7.4.2.1. Antibodies
    • 7.4.2.2. DNA Template
    • 7.4.2.3. DNA Polymerase
    • 7.4.2.4. Oligonucleotide Primers
    • 7.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 7.4.2.6. Buffer
  • 7.4.3. Assay Kits
  • 7.4.4. Consumables
• 7.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 7.5.1. Infectious Disease
  • 7.5.2. Diabetes
  • 7.5.3. Cardiology
  • 7.5.4. Oncology
  • 7.5.5. Nephrology
  • 7.5.6. Autoimmune Disease
  • 7.5.7. Dermatology
  • 7.5.8. Wound Care
  • 7.5.9. Others
• 7.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 7.6.1. Hospitals & Clinics
  • 7.6.2. Diagnostics Laboratories
  • 7.6.3. Academic and Research Institutes
  • 7.6.4. Biopharmaceutical Companies
• 7.7. Market Attractiveness Analysis

8. East Asia Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 8.2.1. by Country
  • 8.2.2. by Product Type
  • 8.2.3. By Disease Area
  • 8.2.4. by End User
• 8.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 8.4.1. Instruments
    • 8.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 8.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 8.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 8.4.1.4. Microarrays
  • 8.4.2. Reagent
    • 8.4.2.1. Antibodies
    • 8.4.2.2. DNA Template
    • 8.4.2.3. DNA Polymerase
    • 8.4.2.4. Oligonucleotide Primers
    • 8.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 8.4.2.6. Buffer
  • 8.4.3. Assay Kits
  • 8.4.4. Consumables
• 8.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 8.5.1. Infectious Disease
  • 8.5.2. Diabetes
  • 8.5.3. Cardiology
  • 8.5.4. Oncology
  • 8.5.5. Nephrology
  • 8.5.6. Autoimmune Disease
  • 8.5.7. Dermatology
  • 8.5.8. Wound Care
  • 8.5.9. Others
• 8.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 8.6.1. Hospitals & Clinics
  • 8.6.2. Diagnostics Laboratories
  • 8.6.3. Academic and Research Institutes
  • 8.6.4. Biopharmaceutical Companies
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 9.2.1. by Country
  • 9.2.2. by Product Type
  • 9.2.3. By Disease Area
  • 9.2.4. by End User
• 9.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
• 9.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 9.4.1. Instruments
    • 9.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 9.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 9.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 9.4.1.4. Microarrays
  • 9.4.2. Reagent
    • 9.4.2.1. Antibodies
    • 9.4.2.2. DNA Template
    • 9.4.2.3. DNA Polymerase
    • 9.4.2.4. Oligonucleotide Primers
    • 9.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 9.4.2.6. Buffer
  • 9.4.3. Assay Kits
  • 9.4.4. Consumables
• 9.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 9.5.1. Infectious Disease
  • 9.5.2. Diabetes
  • 9.5.3. Cardiology
  • 9.5.4. Oncology
  • 9.5.5. Nephrology
  • 9.5.6. Autoimmune Disease
  • 9.5.7. Dermatology
  • 9.5.8. Wound Care
  • 9.5.9. Others
• 9.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 9.6.1. Hospitals & Clinics
  • 9.6.2. Diagnostics Laboratories
  • 9.6.3. Academic and Research Institutes
  • 9.6.4. Biopharmaceutical Companies
• 9.7. Market Attractiveness Analysis

10. Latin America Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 10.2.1. by Country
  • 10.2.2. by Product Type
  • 10.2.3. By Disease Area
  • 10.2.4. by End User
• 10.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 10.4.1. Instruments
    • 10.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 10.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 10.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 10.4.1.4. Microarrays
  • 10.4.2. Reagent
    • 10.4.2.1. Antibodies
    • 10.4.2.2. DNA Template
    • 10.4.2.3. DNA Polymerase
    • 10.4.2.4. Oligonucleotide Primers
    • 10.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 10.4.2.6. Buffer
  • 10.4.3. Assay Kits
  • 10.4.4. Consumables
• 10.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 10.5.1. Infectious Disease
  • 10.5.2. Diabetes
  • 10.5.3. Cardiology
  • 10.5.4. Oncology
  • 10.5.5. Nephrology
  • 10.5.6. Autoimmune Disease
  • 10.5.7. Dermatology
  • 10.5.8. Wound Care
  • 10.5.9. Others
• 10.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 10.6.1. Hospitals & Clinics
  • 10.6.2. Diagnostics Laboratories
  • 10.6.3. Academic and Research Institutes
  • 10.6.4. Biopharmaceutical Companies
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Molecular Diagnostics Market Outlook: Historical (2019-2023) and Forecast (2024 - 2031)

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Bn ) Analysis by Market, 2019-2023
  • 11.2.1. by Country
  • 11.2.2. by Product Type
  • 11.2.3. By Disease Area
  • 11.2.4. by End User
• 11.3. Current Market Size (US$ Bn ) Forecast by Country, 2024 - 2031
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast by Product Type, 2024 - 2031
  • 11.4.1. Instruments
    • 11.4.1.1. Polymerase Chain Reaction (PCR) Systems
    • 11.4.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
    • 11.4.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
    • 11.4.1.4. Microarrays
  • 11.4.2. Reagent
    • 11.4.2.1. Antibodies
    • 11.4.2.2. DNA Template
    • 11.4.2.3. DNA Polymerase
    • 11.4.2.4. Oligonucleotide Primers
    • 11.4.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
    • 11.4.2.6. Buffer
  • 11.4.3. Assay Kits
  • 11.4.4. Consumables
• 11.5. Current Market Size (US$ Bn ) Forecast By Disease Area, 2024 - 2031
  • 11.5.1. Infectious Disease
  • 11.5.2. Diabetes
  • 11.5.3. Cardiology
  • 11.5.4. Oncology
  • 11.5.5. Nephrology
  • 11.5.6. Autoimmune Disease
  • 11.5.7. Dermatology
  • 11.5.8. Wound Care
  • 11.5.9. Others
• 11.6. Current Market Size (US$ Bn ) Forecast by End User, 2024 - 2031
  • 11.6.1. Hospitals & Clinics
  • 11.6.2. Diagnostics Laboratories
  • 11.6.3. Academic and Research Institutes
  • 11.6.4. Biopharmaceutical Companies
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2024
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Becton, Dickinson and Company
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Bio-Rad Laboratories Inc
    • 12.3.2.1. Overview
    • 12.3.2.2. Segments and Products
    • 12.3.2.3. Key Financials
    • 12.3.2.4. Market Developments
    • 12.3.2.5. Market Strategy
  • 12.3.3. Thermo Fisher Scientific Inc.
    • 12.3.3.1. Overview
    • 12.3.3.2. Segments and Products
    • 12.3.3.3. Key Financials
    • 12.3.3.4. Market Developments
    • 12.3.3.5. Market Strategy
  • 12.3.4. Merck KGaA
    • 12.3.4.1. Overview
    • 12.3.4.2. Segments and Products
    • 12.3.4.3. Key Financials
    • 12.3.4.4. Market Developments
    • 12.3.4.5. Market Strategy
  • 12.3.5. Agilent Technologies, Inc.
    • 12.3.5.1. Overview
    • 12.3.5.2. Segments and Products
    • 12.3.5.3. Key Financials
    • 12.3.5.4. Market Developments
    • 12.3.5.5. Market Strategy
  • 12.3.6. Hoffmann la roche
    • 12.3.6.1. Overview
    • 12.3.6.2. Segments and Products
    • 12.3.6.3. Key Financials
    • 12.3.6.4. Market Developments
    • 12.3.6.5. Market Strategy
  • 12.3.7. Qiagen N.V.
    • 12.3.7.1. Overview
    • 12.3.7.2. Segments and Products
    • 12.3.7.3. Key Financials
    • 12.3.7.4. Market Developments
    • 12.3.7.5. Market Strategy
  • 12.3.8. Illumina, Inc.
    • 12.3.8.1. Overview
    • 12.3.8.2. Segments and Products
    • 12.3.8.3. Key Financials
    • 12.3.8.4. Market Developments
    • 12.3.8.5. Market Strategy
  • 12.3.9. DiaSorin S.p.A
    • 12.3.9.1. Overview
    • 12.3.9.2. Segments and Products
    • 12.3.9.3. Key Financials
    • 12.3.9.4. Market Developments
    • 12.3.9.5. Market Strategy
  • 12.3.10. Hologic Inc.
    • 12.3.10.1. Overview
    • 12.3.10.2. Segments and Products
    • 12.3.10.3. Key Financials
    • 12.3.10.4. Market Developments
    • 12.3.10.5. Market Strategy
  • 12.3.11. Siemens Healthineers AG
    • 12.3.11.1. Overview
    • 12.3.11.2. Segments and Products
    • 12.3.11.3. Key Financials
    • 12.3.11.4. Market Developments
    • 12.3.11.5. Market Strategy
  • 12.3.12. Seegene, Inc.
    • 12.3.12.1. Overview
    • 12.3.12.2. Segments and Products
    • 12.3.12.3. Key Financials
    • 12.3.12.4. Market Developments
    • 12.3.12.5. Market Strategy
  • 12.3.13. Grifols, S.A.
    • 12.3.13.1. Overview
    • 12.3.13.2. Segments and Products
    • 12.3.13.3. Key Financials
    • 12.3.13.4. Market Developments
    • 12.3.13.5. Market Strategy
  • 12.3.14. bioMerieux
    • 12.3.14.1. Overview
    • 12.3.14.2. Segments and Products
    • 12.3.14.3. Key Financials
    • 12.3.14.4. Market Developments
    • 12.3.14.5. Market Strategy
  • 12.3.15. QuidelOrtho Corporation
    • 12.3.15.1. Overview
    • 12.3.15.2. Segments and Products
    • 12.3.15.3. Key Financials
    • 12.3.15.4. Market Developments
    • 12.3.15.5. Market Strategy
  • 12.3.16. RapidBio
    • 12.3.16.1. Overview
    • 12.3.16.2. Segments and Products
    • 12.3.16.3. Key Financials
    • 12.3.16.4. Market Developments
    • 12.3.16.5. Market Strategy
  • 12.3.17. Abbott Laboratories
    • 12.3.17.1. Overview
    • 12.3.17.2. Segments and Products
    • 12.3.17.3. Key Financials
    • 12.3.17.4. Market Developments
    • 12.3.17.5. Market Strategy
  • 12.3.18. Danaher Corporation
    • 12.3.18.1. Overview
    • 12.3.18.2. Segments and Products
    • 12.3.18.3. Key Financials
    • 12.3.18.4. Market Developments
    • 12.3.18.5. Market Strategy

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료